Erythropoietin

(redirected from Epoetin)
Also found in: Dictionary, Thesaurus, Medical.

erythropoietin

[ə‚rith·rə′pȯi·ət·ən]
(biochemistry)
A hormone, thought to be produced by the kidneys, that regulates erythropoiesis, at least in higher vertebrates.

Erythropoietin

 

a hormone that stimulates the formation of erythrocytes in bone marrow. Characterized as a glycoprotein, erythropoietin has a carbohydrate content of 35 percent. It has a molecular weight of 30,000–40,000 and possesses antigenic properties. Erythropoietin is inactivated by neuraminidase, trypsin, chymotrypsin, and papain.

Erythropoietin was discovered by the French researchers F. Corneau and C. de Flandre in 1906 in rabbit serum that they tested after drawing blood. The hormone is found in low concentrations under normal physiological conditions, but the levels increase when the subject is in a state of hypoxia as a result of the loss of blood, a decrease in the oxygen content of the air, or various forms of anemia. Most scientists believe that erythropoietin is formed in the kidneys. When the hormone acts on stem cells in bone marrow, it causes their differentiation into cells of the erythroid series.

REFERENCES

Fedorov, N. A., and M. G. Kakhetelidze. Eritropoetin. Moscow, 1973.
Normal’noe krovetvorenie i ego reguliatsiia. Moscow, 1976.
Gordon, A. S. Regulation of Hematopoiesis, vol. 1. New York [1970].

N. A. FEDOROV

References in periodicals archive ?
The analyses first modeled the facility use of epoetin and other injectable drugs with cubic splines (with knots located at the 5th, 25th, 50th, 75th, and 95th percentiles).
Darbepoetin alfa, marketed as Arandesp, and epoetin alfa, marketed as Epogen o and Procrit, are the ESAs approved in the United States; they are administered as often as one to three times per week.
Despite the use of epoetin alfa, approximately 35% of patients with ESKD have persistent anemia (Deved et al.
Published studies have evaluated dosing patterns, drug costs, dosing ratios between epoetin alfa and darbepoetin alfa, and hematological outcomes of ESAs (Hymes et al.
Of the 101 patients, most (n = 78) were receiving either darbepoetin alfa (n = 66) or epoetin beta (n = 12); a minority (n = 6) were not sure what ESA they were currently receiving.
About half of the deaths in each group occurred in the first 7 days after receiving the drug or placebo; about 4% of those on epoetin alfa died from an intracranial hemorrhage, compared with 1% of those on placebo.
IV epoetin was dosed up to three times weekly compared to CERA dosed once every two weeks or once every four weeks.
For 16 weeks, they gave Procrit, a brand of epoetin alfa, in a weekly injection to 58 volunteers who had less than 11.
Blood and urines were collected immediately before administration of saline or epoetin alfa.
Based upon the favorable effects of recombinant epoetin alfa (Procrit) on cognitive function, quality of life, and asthenia in a small pilot study, a much larger clinical trial is underway, according to Dr.
Amgen retained the exclusive right to promote and sell its brand of Epoetin alfa, EPOGEN, for dialysis use in the United States.
Noninferiority to Epoetin in Maintenance of Hemoglobin (Hb) : The difference between the OMONTYS and epoetin-treated groups in the mean change in Hb levels from baseline to the study evaluation period (calculated as the mean of all measurements during weeks 29-36) in EMERALD 1 and 2 was -0.